Uppsala, Sweden, May 14, 2020 – Oasmia Pharmaceutical AB (OMAX.GR), announces that at the Extraordinary General Meeting (“EGM”) of the Company held earlier today, all resolutions were duly passed. These included confirmation of the appointments of Anders Härfstrand as the new Chairman of the Board and Birgit Stattin Norinder as Board Member, with immediate effect. Jörgen Olsson, former Chairman, and Gunilla Öhman, former Board member, will step down.

For more information:

Oasmia Pharmaceutical AB
Francois Martelet, Chief Executive Officer
Michael af Winklerfelt, Chief Financial Officer
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com

Consilium Strategic Communications
Jonathan Birt, Chris Welsh
Phone: +44 (0)20 3709 5700
E-mail: oasmia@conailium-comms.com

The information was submitted for publication, through the agency of the contact persons set out above, at 16.30 CET on May 14, 2020.
About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Oasmia produces novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on Oasmia’s proprietary technology platform XR-17. Oasmia has been successful in driving its first product candidate, Apealea® (paclitaxel micellar), through clinical development, and has applied for and achieved market approval in the European Union and other territories. Oasmia is in the process of transitioning into the commercialization phase of the product Apealea and making the product accessible to patients via its partnership with Elevar and its existing operations and partnerships in its retained territories.